Search results
Added:
3 months ago
Source:
Cardiac Failure Review Journal
Delays in diagnosis and treatment for patients with suspected heart failure (HF) in the community can lead to preventable hospitalisations and deaths. A new modelling study by Dr Kieran Docherty and colleagues suggests that early initiation of disease-modifying therapies in select patients at the time of an elevated natriuretic peptide test could significantly reduce these adverse outcomes…
View more
Added:
4 months ago
Source:
Radcliffe Cardiology
A new study has revealed significant delays in the diagnosis of transthyretin amyloid cardiomyopathy (ATTR-CM) following an initial diagnosis of heart failure (HF), with the median time to diagnosis exceeding one year.¹ Timely identification of ATTR-CM is critical to reduce morbidity and mortality, as effective treatments are available.²MethodologyThis retrospective cohort study analysed data…
View more
Added:
1 year ago
EASD 24 - We are joined by Professor John McMurray (University of Glasgow, UK) to discuss the key findings from a diabetes subgroup analysis of the FINEARTS-HF study.Interview Questions:1. What is the reasoning behind this analysis?2. What was the study design and patient cohort?3. What are the key findings?4. In your opinion, what can explain this risk reduction?5. What are the take-home…
View more
Added:
1 year ago
ESC Congress 2024 — Finerenone improved outcomes in two trials in patients with CKD with T2D, and in patients with HFmrEF and HFpEF.Investigator, Dr Muthiah Vaduganathan (Brigham and Women’s Hospital, US) joins us in London to discuss the findings from the FINE-HEART pooled analysis (Bayer).FINE-HEART is a pre-specified, exploratory pooled analysis combining data from three phase III clinical…
View more
Added:
3 months ago
Source:
Arrhythmia and Electrophysiology Review
For patients with heart failure (HF) and left bundle-branch block (LBBB), left bundle-branch pacing (LBBP) has been proposed as an alternative to the standard biventricular pacing (BiVP).¹ A new randomised trial, HeartSync-LBBP, has found that LBBP leads to superior long-term clinical outcomes compared with BiVP in this patient population.²MethodologyThe HeartSync-LBBP trial was a multicentre,…
View more
Added:
3 months ago
Source:
Cardiac Failure Review
The optimal timing for complete revascularisation in patients with ST-segment elevation myocardial infarction (STEMI) and multi-vessel disease who also present with heart failure is a key clinical question. A pre-specified subgroup analysis of the OPTION-STEMI trial suggests that a staged approach may be preferable to immediate complete revascularisation in this high-risk patient group…
View more
ESC HF 25: SCD-PROTECT
Added:
1 year ago
Video
Added:
1 week ago
Dr Harriette Van Spall (McMaster University, CA) hosts this Masterclass on the contemporary management of heart failure with preserved and mildly reduced ejection fraction, joined by Professor Maja Čikeš (University Hospital Centre Zagreb, HR) for a focused review of the datasets that are redefining treatment in HFpEF/HFmrEF. Framed around the transition from a field once dominated by therapeutic…
View more
Molecular Mechanisms of the Failing Heart
Added:
2 years ago
Review Article
Added:
2 years ago
HFA 24 - We are joined by Dr Muthiah Vaduganathan (Brigham and Women’s Hospital, US) to discuss the design and baseline characteristics of the FINE-HEART(Bayer) integrated pooled analysis of finerenone, an on-steroidal mineralocorticoid receptor (MRA) antagonist, in over 19000 patients with heart failure and CKD.FINE-HEART includes patients with type 2 diabetes, chronic kidney disease and/or…
View more